Bigfoot Biomedical Bigfoot Unity
The Bigfoot Unity platform. [Image courtesy of Bigfoot Biomedical]

Bigfoot Biomedical today announced study data demonstrating the potential of its Bigfoot Unity system for diabetes management.

The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin they need.

Milpitas, California-based Bigfoot Biomedical published the six-month retrospective analysis in the American Diabetes Association’s (ADA) journal, Clinical Diabetes. Dr. Bantwal Baliga, East Alabama Endocrinology, served as lead author of the manuscript.

In an initial real-world, 58-person cohort, results highlight Bigfoot Unity’s ability to support rapid and durable improvement in glucose control. It evaluated the system in people with diabetes who use multiple daily injections of insulin.

Get the full story at our sister site, Drug Delivery Business News.